Recent advances in mRNA vaccine delivery

In recent years, messenger RNA (mRNA) vaccines have been intensively studied in the fields of cancer immunotherapy and infectious diseases because of their excellent efficacy and safety profile. Despite significant progress in the rational design of mRNA vaccines and elucidation of their mechanism of action, their widespread application is limited by the development of safe and effective delivery systems that protect them from ubiquitous ribonucleases (RNases), facilitate their entry into cells and subsequent escape from endosomes, and target them to lymphoid organs or particular cells. Some mRNA vaccines based on lipid carriers have entered clinical trials. Vaccines based on polymers, while not as clinically advanced as lipid vectors, show considerable potentials. In this review, we discuss the necessity of formulating mRNA vaccines with delivery systems, and we provide an overview of reported delivery systems.

[1]  Kaoru Tominaga,et al.  Activation of innate immune antiviral response by NOD2 , 2009, Nature Immunology.

[2]  J. Castle,et al.  Translation of genomics-guided RNA-based personalised cancer vaccines: towards the bedside , 2014, British Journal of Cancer.

[3]  S. Akira,et al.  Species-Specific Recognition of Single-Stranded RNA via Toll-like Receptor 7 and 8 , 2004, Science.

[4]  U. Şahin,et al.  Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. , 2006, Blood.

[5]  C. Buonsanti,et al.  CD8 T‐cell priming upon mRNA vaccination is restricted to bone‐marrow‐derived antigen‐presenting cells and may involve antigen transfer from myocytes , 2015, Immunology.

[6]  J. Ruysschaert,et al.  Formation and intracellular trafficking of lipoplexes and polyplexes. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[7]  T. Schlake,et al.  Developing mRNA-vaccine technologies , 2012, RNA biology.

[8]  Robert Langer,et al.  Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy. , 2017, Nano letters.

[9]  Marion Jurk,et al.  Identification of RNA Sequence Motifs Stimulating Sequence-Specific TLR8-Dependent Immune Responses1 , 2008, The Journal of Immunology.

[10]  Daniel G. Anderson,et al.  Non-viral vectors for gene-based therapy , 2014, Nature Reviews Genetics.

[11]  C. Pichon,et al.  Lipid-based mRNA vaccine delivery systems , 2015, Expert review of vaccines.

[12]  Ö. Türeci,et al.  Uptake of synthetic naked RNA by skin-resident dendritic cells via macropinocytosis allows antigen expression and induction of T-cell responses in mice , 2016, Cancer Immunology, Immunotherapy.

[13]  R. Deering,et al.  Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines , 2014, Expert opinion on drug delivery.

[14]  F. Szoka,et al.  Synthesis, characterization, and evaluation of ionizable lysine-based lipids for siRNA delivery. , 2013, Bioconjugate chemistry.

[15]  B. Ryffel,et al.  mRNA-based cancer vaccine: prevention of B16 melanoma progression and metastasis by systemic injection of MART1 mRNA histidylated lipopolyplexes , 2007, Cancer Gene Therapy.

[16]  B. Neyns,et al.  Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  K. Kataoka,et al.  Treatment of neurological disorders by introducing mRNA in vivo using polyplex nanomicelles. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[18]  Rolf Suter,et al.  Polyethylenimine-based polyplex delivery of self-replicating RNA vaccines. , 2016, Nanomedicine : nanotechnology, biology, and medicine.

[19]  U. Şahin,et al.  Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[20]  E. Paoletti,et al.  Purification of mRNA guanylyltransferase and mRNA (guanine-7-) methyltransferase from vaccinia virions. , 1975, The Journal of biological chemistry.

[21]  R. Langer,et al.  mRNA vaccine delivery using lipid nanoparticles. , 2016, Therapeutic delivery.

[22]  M. Gore,et al.  Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma , 2013, British Journal of Cancer.

[23]  Wenzhong Li,et al.  Non-viral gene delivery methods. , 2013, Current pharmaceutical biotechnology.

[24]  Shubiao Zhang,et al.  Toxicity of cationic lipids and cationic polymers in gene delivery. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[25]  C. Pichon,et al.  Histidine-rich peptides and polymers for nucleic acids delivery. , 2001, Advanced drug delivery reviews.

[26]  M. Fotin‐Mleczek,et al.  mRNA-based vaccines synergize with radiation therapy to eradicate established tumors , 2014, Radiation oncology.

[27]  R. Flavell,et al.  Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3 , 2001, Nature.

[28]  Shubiao Zhang,et al.  The headgroup evolution of cationic lipids for gene delivery. , 2013, Bioconjugate chemistry.

[29]  U. Şahin,et al.  Current Developments in Actively Personalized Cancer Vaccination with a Focus on RNA as the Drug Format. , 2015, Progress in tumor research.

[30]  Elmar Wahle,et al.  Poly(A) Tail Shortening by a Mammalian Poly(A)-specific 3′-Exoribonuclease* , 1997, The Journal of Biological Chemistry.

[31]  A. Pasquinelli,et al.  Reverse 5' caps in RNAs made in vitro by phage RNA polymerases. , 1995, RNA.

[32]  S. Pascolo.  Vaccination with messenger RNA (mRNA). , 2008, Handbook of experimental pharmacology.

[33]  W. Cao,et al.  Deviation from major codons in the Toll‐like receptor genes is associated with low Toll‐like receptor expression , 2005, Immunology.

[34]  S. Govindarajan,et al.  Codon bias and heterologous protein expression. , 2004, Trends in biotechnology.

[35]  H. Rammensee,et al.  Plasmid DNA- and messenger RNA-based anti-cancer vaccination. , 2008, Immunology letters.

[36]  Tao Gong,et al.  Enhanced intranasal delivery of mRNA vaccine by overcoming the nasal epithelial barrier via intra- and paracellular pathways. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[37]  M. Abbaszadegan,et al.  Neoantigen in esophageal squamous cell carcinoma for dendritic cell-based cancer vaccine development , 2014, Medical Oncology.

[38]  G. Lenzen,et al.  Induction of virus‐specific cytotoxic T lymphocytes in vivo by liposome‐entrapped mRNA , 1993, European journal of immunology.

[39]  Daniel G. Anderson,et al.  Knocking down barriers: advances in siRNA delivery , 2009, Nature Reviews Drug Discovery.

[40]  D. Weissman,et al.  Zika virus protection by a single low dose nucleoside modified mRNA vaccination , 2017, Nature.

[41]  Daniel G. Anderson,et al.  Advances in the delivery of RNA therapeutics: from concept to clinical reality , 2017, Genome Medicine.

[42]  C. Mandl,et al.  A cationic nanoemulsion for the delivery of next-generation RNA vaccines. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[43]  V. Torchilin.  Recent advances with liposomes as pharmaceutical carriers , 2005, Nature Reviews Drug Discovery.

[44]  J. Rosenecker,et al.  Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems , 2017, Gene Therapy.

[45]  F. Veiga,et al.  Poloxamers, poloxamines and polymeric micelles: Definition, structure and therapeutic applications in cancer , 2017, Journal of Polymer Research.

[46]  Justin M. Richner,et al.  Modified mRNA Vaccines Protect against Zika Virus Infection , 2017, Cell.

[47]  Daniel G. Anderson,et al.  Semi-automated synthesis and screening of a large library of degradable cationic polymers for gene delivery. , 2003, Angewandte Chemie.

[48]  K. McCullough,et al.  Double‐stranded secondary structures on mRNA induce type I interferon (IFN α/β) production and maturation of mRNA‐transfected monocyte‐derived dendritic cells , 2005, The journal of gene medicine.

[49]  K. Kataoka,et al.  Messenger RNA-based therapeutics for the treatment of apoptosis-associated diseases , 2015, Scientific Reports.

[50]  W. Ahn,et al.  Low toxicity of cationic lipid-based emulsion for gene transfer. , 2004, Biomaterials.

[51]  C. Pichon,et al.  On the gene delivery efficacies of pH-sensitive cationic lipids via endosomal protonation: a chemical biology investigation. , 2004, Chemistry & biology.

[52]  Daniel G. Anderson,et al.  Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose , 2016, Proceedings of the National Academy of Sciences.

[53]  Man Li,et al.  Induction of HIV-1 gag specific immune responses by cationic micelles mediated delivery of gag mRNA , 2016, Drug delivery.

[54]  D. Weissman,et al.  mRNA vaccines — a new era in vaccinology , 2018, Nature Reviews Drug Discovery.

[55]  S. Gordon,et al.  Scavenger receptors in innate immunity. , 2002, Current opinion in immunology.

[56]  F. Szoka,et al.  Physicochemical characterization and purification of cationic lipoplexes. , 1999, Biophysical journal.

[57]  G. Kemble,et al.  Generation of Live Attenuated Novel Influenza Virus A/California/7/09 (H1N1) Vaccines with High Yield in Embryonated Chicken Eggs , 2009, Journal of Virology.

[58]  L. Bossi,et al.  The influence of codon context on genetic code translation , 1980, Nature.

[59]  Youngwook Kim,et al.  Influence of nano-carrier architecture on in vitro siRNA delivery performance and in vivo biodistribution: polyplexes vs micelleplexes. , 2011, ACS nano.

[60]  Khalid A. Hajj,et al.  Tools for translation: non-viral materials for therapeutic mRNA delivery , 2017 .

[61]  V. Torchilin,et al.  Multifunctional polymeric micelles for delivery of drugs and siRNA , 2014, Front. Pharmacol..

[62]  D. Melton,et al.  Functional messenger RNAs are produced by SP6 in vitro transcription of cloned cDNAs. , 1984, Nucleic acids research.

[63]  S. Aamdal,et al.  Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells , 2016, Oncoimmunology.

[64]  H. Rammensee,et al.  Genetic Vaccines and Therapy , 2006 .

[65]  Ö. Türeci,et al.  Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation , 2011, Gene Therapy.

[66]  A. Göpferich,et al.  Polyethylenimine-based non-viral gene delivery systems. , 2005, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[67]  K. G. Rajeev,et al.  Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[68]  D. Davies,et al.  The toll-like receptor 3:dsRNA signaling complex. , 2009, Biochimica et biophysica acta.

[69]  Yuhua Wang,et al.  Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer. , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[70]  U. Şahin,et al.  Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. , 2010, Cancer research.

[71]  E. Gilboa,et al.  Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen , 2006, Cancer Immunology, Immunotherapy.

[72]  C. Heirman,et al.  Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy. , 2012, Cancer research.

[73]  G. Acsadi,et al.  Direct gene transfer into mouse muscle in vivo. , 1990, Science.

[74]  J. Rosenecker,et al.  PEGylation Improves Nanoparticle Formation and Transfection Efficiency of Messenger RNA , 2011, Pharmaceutical Research.

[75]  J. R. Vargas,et al.  Charge-altering releasable transporters (CARTs) for the delivery and release of mRNA in living animals , 2017, Proceedings of the National Academy of Sciences.

[76]  T. Schlake,et al.  Protein expression from exogenous mRNA: Uptake by receptor-mediated endocytosis and trafficking via the lysosomal pathway , 2011, RNA biology.

[77]  A. Thess,et al.  Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect , 2012, The journal of gene medicine.

[78]  Hiroki Kato,et al.  Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[79]  G. Vanham,et al.  Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[80]  Man Li,et al.  Engineering intranasal mRNA vaccines to enhance lymph node trafficking and immune responses. , 2017, Acta biomaterialia.

[81]  M. Fotin‐Mleczek,et al.  Messenger RNA-based Vaccines With Dual Activity Induce Balanced TLR-7 Dependent Adaptive Immune Responses and Provide Antitumor Activity , 2011, Journal of immunotherapy.

[82]  R. Granstein,et al.  Induction of anti-tumor immunity with epidermal cells pulsed with tumor-derived RNA or intradermal administration of RNA. , 2000, The Journal of investigative dermatology.

[83]  S. Fukushima,et al.  Messenger RNA delivery of a cartilage-anabolic transcription factor as a disease-modifying strategy for osteoarthritis treatment , 2016, Scientific Reports.

[84]  B. Malaekeh-Nikouei,et al.  Progress in the development of lipopolyplexes as efficient non-viral gene delivery systems. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[85]  P. Eilers,et al.  A phase I/IIa immunotherapy trial of HIV-1-infected patients with Tat, Rev and Nef expressing dendritic cells followed by treatment interruption. , 2012, Clinical immunology.

[86]  F. Wurm.  Production of recombinant protein therapeutics in cultivated mammalian cells , 2004, Nature Biotechnology.

[87]  K. Kataoka,et al.  Systemic delivery of messenger RNA for the treatment of pancreatic cancer using polyplex nanomicelles with a cholesterol moiety. , 2016, Biomaterials.

[88]  Özlem Türeci,et al.  Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy , 2016, Nature.

[89]  S. Akira,et al.  Nucleic acid agonists for Toll‐like receptor 7 are defined by the presence of uridine ribonucleotides , 2006, European journal of immunology.

[90]  Osamu Takeuchi,et al.  Recognition of 5' triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus. , 2009, Immunity.

[91]  Alexei A. Sharov,et al.  Database for mRNA Half-Life of 19 977 Genes Obtained by DNA Microarray Analysis of Pluripotent and Differentiating Mouse Embryonic Stem Cells , 2008, DNA research : an international journal for rapid publication of reports on genes and genomes.

[92]  G. Vanham,et al.  Challenges and advances towards the rational design of mRNA vaccines. , 2013, Trends in molecular medicine.

[93]  C. Pichon,et al.  Enhancement of dendritic cells transfection in vivo and of vaccination against B16F10 melanoma with mannosylated histidylated lipopolyplexes loaded with tumor antigen messenger RNA. , 2011, Nanomedicine : nanotechnology, biology, and medicine.

[94]  D. Weissman,et al.  Nucleoside Modified mRNA Vaccines for Infectious Diseases. , 2017, Methods in molecular biology.

[95]  Shigeo Matsuda,et al.  Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo** , 2012, Angewandte Chemie.

[96]  C. Pichon,et al.  Single histidine residue in head-group region is sufficient to impart remarkable gene transfection properties to cationic lipids: evidence for histidine-mediated membrane fusion at acidic pH , 2003, Gene Therapy.

[97]  H. Rammensee,et al.  Polarization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccines , 2004, Cellular and Molecular Life Sciences CMLS.

[98]  M. Ogris,et al.  Peptide-mediated RNA delivery: a novel approach for enhanced transfection of primary and post-mitotic cells. , 2001, Nucleic acids research.

[99]  Houping Ni,et al.  Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. , 2005, Immunity.

[100]  A. Hinnebusch,et al.  Regulation of Translation Initiation in Eukaryotes: Mechanisms and Biological Targets , 2009, Cell.

[101]  L. Defrancesco.  The 'anti-hype' vaccine , 2017, Nature Biotechnology.

[102]  Yuhua Wang,et al.  mRNA Vaccine with Antigen-Specific Checkpoint Blockade Induces an Enhanced Immune Response against Established Melanoma. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[103]  F. Brasseur,et al.  Messenger RNA-Electroporated Dendritic Cells Presenting MAGE-A3 Simultaneously in HLA Class I and Class II Molecules1 , 2004, The Journal of Immunology.

[104]  Özlem Türeci,et al.  mRNA-based therapeutics — developing a new class of drugs , 2014, Nature Reviews Drug Discovery.

[105]  K. McCullough,et al.  Self‐replicating RNA vaccine functionality modulated by fine‐tuning of polyplex delivery vehicle structure , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[106]  Shizuo Akira,et al.  Innate Antiviral Responses by Means of TLR7-Mediated Recognition of Single-Stranded RNA , 2004, Science.

[107]  D. Scherman,et al.  A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[108]  R. Rhoads,et al.  Synthesis and properties of mRNAs containing the novel "anti-reverse" cap analogs 7-methyl(3'-O-methyl)GpppG and 7-methyl (3'-deoxy)GpppG. , 2001, RNA.

[109]  H. Rammensee,et al.  Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent , 2007, Gene Therapy.

[110]  D. Peer,et al.  Delivering the right message: Challenges and opportunities in lipid nanoparticles-mediated modified mRNA therapeutics-An innate immune system standpoint. , 2017, Seminars in immunology.

[111]  C. Mandl,et al.  Self-amplifying mRNA vaccines. , 2015, Advances in genetics.

[112]  Meredith A Mintzer,et al.  Nonviral vectors for gene delivery. , 2009, Chemical reviews.

[113]  Mauro Ferrari,et al.  Lipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination. , 2017, Biomaterials.

[114]  J. Ulmer,et al.  Mechanism of action of mRNA-based vaccines , 2017, Expert review of vaccines.

[115]  P. Cullis,et al.  Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[116]  D. G. Gibson,et al.  Rapidly produced SAM® vaccine against H7N9 influenza is immunogenic in mice , 2013, Emerging Microbes & Infections.

[117]  D. Fischer,et al.  A Novel Non-Viral Vector for DNA Delivery Based on Low Molecular Weight, Branched Polyethylenimine: Effect of Molecular Weight on Transfection Efficiency and Cytotoxicity , 1999, Pharmaceutical Research.

[118]  P van Hoogevest,et al.  MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. , 1995, Pharmaceutical biotechnology.

[119]  S. De Santis,et al.  Use of short interfering RNA delivered by cationic liposomes to enable efficient down-regulation of PTPN22 gene in human T lymphocytes , 2017, PloS one.

[120]  Shizuo Akira,et al.  Shared and Unique Functions of the DExD/H-Box Helicases RIG-I, MDA5, and LGP2 in Antiviral Innate Immunity1 , 2005, The Journal of Immunology.

[121]  J. Boudreau,et al.  Engineering dendritic cells to enhance cancer immunotherapy. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[122]  C. Rudolph,et al.  A Single Methylene Group in Oligoalkylamine-Based Cationic Polymers and Lipids Promotes Enhanced mRNA Delivery. , 2016, Angewandte Chemie.

[123]  U. Şahin,et al.  Translating nanoparticulate-personalized cancer vaccines into clinical applications: case study with RNA-lipoplexes for the treatment of melanoma. , 2016, Nanomedicine.

[124]  M. Fotin‐Mleczek,et al.  Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity. , 2016, Vaccine.

[125]  R. Rhoads,et al.  Synthesis and characterization of mRNA cap analogs containing phosphorothioate substitutions that bind tightly to eIF4E and are resistant to the decapping pyrophosphatase DcpS. , 2008, RNA.

[126]  Robert Langer,et al.  Rapid Optimization of Gene Delivery by Parallel End-modification of Poly(β-amino ester)s. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[127]  Xun Sun,et al.  Lymph node targeting strategies to improve vaccination efficacy , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[128]  Ö. Türeci,et al.  Tumor vaccination using messenger RNA: prospects of a future therapy. , 2011, Current opinion in immunology.

[129]  Alicia Rodríguez-Gascón,et al.  Development of nucleic acid vaccines: use of self-amplifying RNA in lipid nanoparticles , 2014, International journal of nanomedicine.